Salmefamol
Salmefamol is a drug of the phenethylamine and amphetamine families described as a bronchodilator which was never marketed. It is a β-adrenergic receptor agonist with some selectivity for the β2-adrenergic receptor and has been described as a "sister compound" to salbutamol. However, the drug is more potent, longer-acting, and more lipophilic in comparison to salbutamol. It was intended for inhalational or intravenous administration. Salmefamol was first described in the literature by 1968.